Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of
Celgene Corporation, today announced that the European Medicines
Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has
adopted a positive opinion for OTEZLA® (apremilast), the Company’s oral
selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic
Psoriasis is an immune mediated skin condition characterised by raised
scaly lesions on the skin.
for Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis investment picks